00512 遠大醫藥
按盘价 
8.130 -0.120 (-1.455%) 盈利能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 资产回报率 (%) | 10.392% | 8.377% | 9.576% | 12.631% | 11.642% |
| 股东资金回报率 (%) | 15.607% | 12.834% | 15.105% | 19.508% | 18.279% |
| 资本运用回报率 (%) | 13.402% | 11.201% | 13.065% | 15.510% | 14.136% |
边际利润分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 毛利率 (%) | 57.865% | 61.959% | 62.239% | 61.029% | 63.517% |
| 未计利息、税项、折旧及摊销前利润率 (%) | 29.037% | 28.100% | 32.140% | 35.235% | 37.716% |
| 税前边际利润率 (%) | 24.495% | 22.263% | 26.321% | 32.401% | 32.640% |
| 纯利率 (%) | 21.197% | 17.854% | 21.746% | 27.943% | 28.218% |
变现能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 流动比率 (X) | 1.221 X | 1.224 X | 1.067 X | 1.218 X | 1.236 X |
| 速动比率 (X) | 1.012 X | 0.982 X | 0.859 X | 1.017 X | 1.014 X |
财务杠杆分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 总负债 / 总资产比率 (%) | 33.875% | 32.177% | 36.486% | 36.160% | 33.208% |
| 总债项 / 总资产比率 (%) | 17.776% | 15.120% | 20.005% | 17.313% | 14.062% |
| 净债项 / 总资产比率 (%) | 12.411% | 9.169% | 13.550% | 8.989% | 3.248% |
| 总债项 / 股东资金比率 (%) | 26.968% | 22.459% | 31.649% | 27.221% | 21.250% |
| 长期债项 / 股东资金比率 (%) | 7.873% | 6.938% | 8.645% | 11.375% | 7.240% |
| 净债项 / 股东资金比率 (%) | 18.828% | 13.620% | 21.437% | 14.133% | 4.908% |
| 净现金 / (债项) ($) | (31.02亿) | (20.65亿) | (30.31亿) | (18.93亿) | (5.52亿) |
| 每股净现金 / (债项) ($) | (0.874) | (0.582) | (0.854) | (0.533) | (0.155) |
| 总债项 / 资本运用比率 (%) | 24.121% | 20.283% | 28.117% | 23.534% | 18.834% |
| 利息盈利率 (X) | 16.825 X | 12.427 X | 19.306 X | 30.967 X | 18.965 X |
营运效率分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 存货周转率日数 (日) | 102.630日 | 124.344日 | 124.215日 | 112.878日 | 139.347日 |
| 应收贸易帐周转率日数 (日) | 72.067日 | 68.102日 | 70.823日 | 70.155日 | 83.421日 |
| 应付贸易帐周转率日数 (日) | 39.929日 | 38.187日 | 30.677日 | 29.652日 | 42.998日 |
| 备注： | 实时报价更新时间为28/10/2025 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | HKD 1,169,019 |
| 增长率 | -24.964% |
| 每股盈利/(亏损) | HKD 0.334 |
| 每股账面资产净值 ($) | HKD 4.833 |